Intrathecal medicines
30 results
Applied filters
Fluorescein: informing intrathecal risk assessment
8 July 2025Fluorescein products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Managing an intrathecal chemotherapy service
13 June 2025The intrathecal route is a high-risk route of administration. There are minimum requirements for providing intrathecal chemotherapy.
Understanding risks with intrathecal administration
13 June 2025The intrathecal route is a high-risk route of administration. Incorrect administration of medicines unsafe for this route can result in patient death.
Ziconotide: informing intrathecal risk assessment
16 May 2025Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Clonidine: informing intrathecal risk assessment
16 May 2025Clonidine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Baclofen: informing intrathecal risk assessment
7 May 2025Baclofen products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Shelf lives of aseptically prepared medicines in NRFit syringes
19 December 2024Provision of intrathecal and epidural injections in NRFit syringes may involve extrapolation of stability data from luer lock systems
Intrathecal administration
All our advice on using intrathecal medicines safely.
Choosing an injectable medicine for intrathecal administration
11 August 2022The intrathecal route is a high risk route of administration. It is essential to consider the properties of the medicinal product when assessing the risk
Morphine: informing intrathecal risk assessment
11 August 2022Morphine sulfate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration